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Abstract
SOX2 is an HMG box containing transcription factor that has been implicated in various types of cancer, but its role
in colorectal cancers (CRC) has not been studied. Here we show that SOX2 is overexpressed in CRC tissues
compared with normal adjacent tissues using immunohistochemical staining and RT-PCR. We also observed an
increased SOX2 expression in nucleus of colorectal cancer tissues (46%, 14/30 cases vs. 7%, 2/30 adjacent tissues).
Furthermore, knockdown of SOX2 in SW620 colorectal cancer cells decreased their growth rates in vitro cell line,
and in vivo in xenograft models. ChIP-Seq analysis of SOX2 revealed a consensus sequence of wwTGywTT. An
integrated expression profiling and ChIP-seq analysis show that SOX2 is involved in the BMP signaling pathway,
steroid metabolic process, histone modifications, and many receptor-mediated signaling pathways such as IGF1R
and ITPR2 (Inositol 1,4,5-triphosphate receptor, type 2).
Introduction
Colorectal cancer is the second most common malig-nancy in cancer patients and cause of cancer-related
mortality (Wiesner et al., 2003). The SOX (SRY-like HMG box)
gene family represents a family of transcriptional factors
characterized by the presence of a conserved HMG (high
mobility group) box in their genes. Thus far, 20 SOX genes
have been identified in humans and mice, and they can be
divided into 10 subgroups on the basis of sequence similarity
and genomic organization (Schepers et al., 2002). SOX genes
bind to the minor groove in DNA to control diverse devel-
opmental processes and play critical roles in cell fate deter-
mination, differentiation, and proliferation (Schepers et al.,
2002). Recently, Takahashi et al. showed that SOX2 is a key
transcription factor that can induce pluripotency in both
mouse and human somatic cells (Li et al., 2004; Takahashi
et al., 2007; Takahashi and Yamanaka, 2006). Importantly,
SOX2 is one of the four factors (OCT4, SOX2, NANOG, and
LIN28) that can reprogram human somatic cells to pluripotent
stem cells that exhibit the essential characteristics of embry-
onic stem (ES) cells (Yu et al., 2007). Giorgetti et al. (2009) also
showed that OCT4 and SOX2 could be used to generate in-
duced pluripotent stem cells from human cord blood.
SOX2 is also overexpressed in several cancers including
gastric cancer, breast cancer, pancreatic cancer, pulmonary
nonsmall cell carcinomas, lung squamous cell carcinomas,
neuroendocrine carcinomas (Gure et al., 2000; Hussenet et al.,
2010; Li et al., 2004; Rodriguez-Pinilla et al., 2007; Sanada et al.,
2006; Wang et al., 2009a). However, the role of SOX2 in co-
lorectal cancer cells has not been studied. Only one study
suggested that levels of SOX2 could be used, together with
two other stem cell markers CD133 and OCT4, for predic-
tion of distant recurrence and poor prognosis of rectal cancer
patients treated with preoperative CRT (Saigusa et al., 2009).
In this study, we have carried out analysis of SOX2 expres-
sion in colorectal cancer tissues and found that it is over-
expressed in the cancerous tissues compared to normal
adjacent tissues. We also carried out in vitro and in vivo
functional analysis of SOX2 by knocking down SOX2 ex-
pression SW620 colorectal cancer cells. Furthermore, we
characterized the SOX2 response program in colorectal cancer
cells through an integrative analysis of expression profiling
and ChIP-seq data.
1Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated
Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China.
2Systems Biology Division, Zhejiang–California International Nanosystems Institute (ZCNI), Zhejiang University, 268 Kaixuan Road,
Hangzhou, Zhejiang, People’s Republic of China.
3Key Laboratory of Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Fujian,
People’s Republic of China.
4Swedish Medical Center, Seattle, Washington.
5Department of Urology, University of Washington, Seattle, Washington.
OMICS A Journal of Integrative Biology
Volume 14, Number 4, 2010




Cell culture, lentiviral transduction, and transfection
SW620, SW480, HT29, CACO2, RKO, and HCT116 colo-
rectal cancer cell lines were obtained from American Type
Culture Collection (Manassas, VA). MISSION shRNA Lenti-
viral Particles for SOX2 knockdown and MISSION Nontarget
shRNA control transduction particles were purchased from
Sigma-Aldrich (St. Louis, MO). The SOX2 target sequences for
shRNA are: CCGGCAGCTCGCAGACCTACATGAACTCG
AGTTCATGTAG GTCTGCGAGCTGTTTTT and CCGGCTG
CCGAGAATCCATGTATATCTCGAGATATACATGGATTC
TCGGCAGTTTTT. SW620 cell stably expressing siRNAs were
generated by transduction with the virus particles followed by
selection using puromycin.
Immunoblot and immunohistochemistry (IHC) analysis
The SOX2 (ab59776) antibody (Abcam Inc., Cambridge,
MA) was used for both analyses. For immunoblot analysis,
some 20mg of total cellular protein was loaded per lane,
separated by 4–12% SDS-polyacrylamide gel electrophoresis,
and then transferred to nitrocellulose (Invitrogen, Carlsbad,
CA) by electroblotting.
We used the IHC services provided by Superchip, Inc.
(Sanford, FL), including antibody optimization, IHC staining,
pathological reading, and scoring by experienced patholo-
gists. Primary antibodies for SOX2 were diluted at 1:250 for
IHC. Secondary antibody was used at 1:200 dilution. For
isotype control antibodies, rabbit IgG (Cat# 0111-01, Southern
Biotech, Birmingham, AL) (5 mg/mL) was used at 1:25 dilu-
tion. Colorectal cancer tissue array (Lot ID: OD-CT-DgCol03)
from Superchip, Inc. (Superchip, Shanghai, China) was used
for IHC. Individual tissue samples were arrayed in duplicate
cores. The tissue array core diameter is 1.5 mm and the core
thickness is 5 mm.
The scoring criteria contain two parameters: percentage of
positive cell population, and staining intensities. For per-
centage of positive cell population, the categories are: 0¼ 0%;
1¼ 1 to 25%; 2¼ 26 to 50%; 3¼ 51 to 75%; 4¼ 76–100%. The
staining intensities were scored as:¼negative staining;þ¼
weak staining intensity; þþ¼medium staining intensity;
þþþ¼ strong staining intensity.
Wound-healing migration assay
About 1.2 million cells were seeded into six-well plates and
incubated at 378C with 5% CO2 until confluent. Wounding
was introduced to the monolayer of cells by scraping the
surface with a sterile pipette tip. The healing process was
examined at 72 h later and recorded with a Canon S 80 digital
camera with a microscope adapter.
Xenograft studies
Some 2104 Cells were harvested, washed, resuspended in
200 mL phosphate-buffered saline (PBS), and was subcutane-
ously injected into the flanks of 5-week-old female nude mice.
Animal experimental procedures were performed strictly in
accordance with the related ethics regulations of our univer-
sity. Tumor sizes were measured in two dimensions with
calipers every week. Tumor volumes (mm3) were calculated
using the following formula: V¼ (lengthwidth2)/2 (Chen
et al., 2008b).
Cell proliferation assays and cell cycle analysis
Cell proliferation was analyzed using the MTT assay kits
(Millipore, Billerica, MA) according to the manufacturer’s
protocol. For cell cycle analysis, cells were harvested and
washed with PBS, followed by fixation with 70% ethanol
overnight at 48C. After washing with PBS twice, the cells were
resuspended in PBS containing 50 mg/mL propidium iodide
and 10 mg/mL RNase A for 30 min at room temperature in
the dark. Samples were analyzed for DNA content by a flow
cytometer (BD Bioscience, San Jose, CA). The cell-cycle phases
were analyzed using CELLQuest software (Becton Dickinson,
San Jose, CA) (Tseng et al., 2009).
Apoptosis analysis
Apoptotic cells were quantified using Annexin V-FITC
apoptosis detection kit (BD Pharmingen, San Diego, CA). The
number of apoptotic cells was analyzed by flow cytometry
(Ex¼ 488 nm; Em¼ 530 nm) (Cho et al., 2008).
Soft agar colony formation assay
For Soft agar colony formation assay, cells were trypsinized
and counted. 10,000 cells were seeded in six-well plates. After
2 weeks of growth, colonies with a diameter greater than
4 mm were counted. Experiments were performed in qua-
druplicates (Foltz et al., 2006; Lee et al., 2010).
Microarray
Total RNA was extracted from cells expressing SOX2
silencing or nonsilencing shRNA with Trizol (Invitrogen) and
followed by further purification step using RNeasy (Qiagen,
Valencia, CA). RNA quality was determined with the Agilent
Bioanalyzer (Palo Alto, CA). Affymetrix U133 plus2 arrays
were used. Microarray hybridization was performed as we
described previously (Lin et al., 2009). Genes that showed
more than a twofold change were considered differentially
expressed.
Chromatin immunoprecipitation (ChIP)-sequencing
About 3106 SW620 cells were used for ChIP according to
the manufacturer’s instruction (Millipore, Bedford, MA, EZ-
Magna ChIP A). Antibodies used for Chip included SOX2
(ab59776, Abcam, Cambridge, MA) and normal IgG (SC-2027,
Santa Cruz, CA). Briefly, cells were fixed by crosslinking with
1% fresh formaldehyde. The fixed cells were resuspended in
lysis buffer. Nuclei were collected and resuspended in nuclei
lysis buffer. Samples were sonicated on ice to the length of
200–500 bp. A total of 5mg antibody and 50mL Dynal protein G
beads were incubated for 2 h at 48C. Sonicated chromatin
were incubated with the protein G-antibody complex over-
night at 4 8C. Precipitated immunocomplex was treated with
proteinase K for 2 h at 658C, and DNA was purified Qiagen
Qiaquick PCR purification kit.
ChIP-seq analysis
ChIP DNA end repairing, adaptor ligation, and amplifica-
tion were performed as described earlier (Lin et al., 2009). The
fragments of about 100 bp (without linkers) were isolated
from agarose gel and used for sequencing using the Solexa/
Illumina 2 G genetic analyzer. Solexa Pipeline Analysis was
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performed as described (Lin et al., 2009). Sequencing tags of
36 nucleotides were mapped to human genome (hg19) using
SOAP program (Wang et al., 2009b) allow two mismatches.
Sequence reads that map to multiple sites in the human ge-
nome were removed. The mapped sequence reads were
converted to ELAND format using our own perl script. MACS
program were used to determine enriched SOX2 peaks using
IgG-ChIP as control. The parameters for MACS were: effec-
tive genome size¼ 2.70eþ 09; tag size¼ 36 (use 50 sequence
36 bp); model fold¼ 32; pvalue cutoff¼ 1.00e-05. The en-
riched peaks were annotated with the HG19 gene annotation
using CisGenome program ( Ji et al., 2008).
To compare the SOX2 targets we identified with the sox2
targets identified in mouse ES cells (Chen et al., 2008a), we
used the CisGenome program ( Ji et al., 2008) to identify the
targets corresponding to the mouse ChIP-Seq data for sox2
using the same parameter of a distance of 50 kb as the cutoff
value. We then identified the gene commons to the two lists
using the homologene table for human and mouse from NCBI
(http://www.ncbi.nlm.nih.gov/homologene).
Validation of differentially expressed genes
and ChIP-seq targets by RT-PCR
Randomly selected differentially expressed genes were
determined by real-time PCR using the ABI PRISM 7900 HT
Sequence Detection System (Applied Biosystems, Carlsbad,
CA). The real-time PCR reactions were carried out in a total
volume of 20mL per well containing SYB master mix reagent
kit (Applied Biosystems) with primers listed (Supplementary
Table 1; http://systemsbiozju.org/data/Supplementary/).
For ChIP-seq analysis, the primers were listed in the Supple-
mentary Table 2.
Results
Increased expression of SOX2 in colorectal cancer tissues
compared with normal colorectal tissues. Increasing evi-
dence shows that SOX2 is expressed in several types of tumors
prompted us to investigate whether SOX2 was also expressed
in colorectal cancers. We performed quantitative RT-PCR on
a panel of 15 fresh colorectal cancer samples and 11 individ-
ual normal colorectal tissues and showed SOX2 mRNA
expression were significantly ( p< 0.01) higher in colorectal
cancer tissues compared with normal tissues (Fig. 1A). To
analyze its protein expression, we performed immunohisto-
chemical staining in 30 colorectal cancer tissues and 30 normal
adjacent tissues. We observed positive immunoreactivities in
colorectal cancer with nucleus staining pattern in 46% (14 of
30) of cancer tissues, compared to only 7% in the adjacent
mucosa tissue cells. Examples of IHC staining results are
shown in Figure 1B. Statistical analysis using Pearson chi-
square (df¼ 1, two-sided) indicates that the difference in SOX2
expression between cancer and adjacent tissues is significant
( p< 0.01).
Western blot analysis of SOX2 in established colorectal
cancer cell lines showed that the levels of SOX2 in RKO,
SW620, Caco2, and HCT116 lines were considerably higher
than those in SW480 and HT29 cell lines (Fig. 1C). SW480 and
SW620 were a matched pair of primary and metastatic pop-
ulation of cells from the same patient (Kubens and Zanker,
1998).
Knockdown of SOX2 decreased the growth
rate of SW620 cells
We used SW620 cells for the experiments, because SW620
cells have the abundant native expression level of SOX2
protein and have the metastatic property among the six co-
lorectal cancer cell lines that we screened. We established
stable SOX2 knockdown clones by lentivirus-mediated
ShRNA gene silencing technology (Sigma-Aldrich, St. Louis,
MO) and determined the SOX2 mRNA and protein expres-
sion in the stable clones using RT-PCR and Western blot
analysis (Fig. 2A and B). MTT assay revealed that knockdown
of SOX2 significantly decreased cell proliferation of SW620
cells (Fig. 2C). To determine the mechanism of the reduced cell
proliferation was due to cell growth arrest or apoptosis, we
performed FACS analyses. Knocking-down of SOX2 resulted
in an accumulation of cells in the G0/G1 phases and a de-
crease of cells in S and G2/M phases (Fig. 2D). However, the
knockdown of SOX2 expression had no measurable effect on
the apoptosis of SW620 cells (Fig. 2E).
SOX2 knockdown decreased cell colony formation
on soft agar and in vivo tumorigenesis potential
Anchorage-independent growth assays demonstrated that
knockdown of SOX2 expression resulted in a reduction in
both the number and sizes of colonies formed on the soft agar
(Fig. 3A). In order to assess the role of SOX2 on colorectal
tumorigenesis in vivo, equal numbers of SW620 cells and
SOX2 knockdown SW620 cells were implanted onto flanks of
5-week-old female nude mice, and the growth of the im-
planted tumors was measured at weeks 1, 2, 3, and 4. The
results of these experiments indicated that knockdown of
SOX2 expression resulted in a dramatic reduction in tumor
volume (Fig. 3B) ( p< 0.01).
Knockdown of SOX2 decreased migratory
property of SW620 cells
Wound-healing assays have been applied for the analysis
of migration of colorectal cancer cells (Dhawan et al., 2005).
We also performed a wound-healing assay to examine the
effect of SOX2 knockdown on cell migration. Cells were see-
ded in six-well plates until confluent, and wounds were in-
troduced by scraping a line on the cell lawn using a pipette tip.
At the time of the next 72 h, cells migration was monitored.
We found that the migration of the parental SW620 cells
across the wounded area was faster than SOX2 knockdown
cells (Fig. 3C). Interestingly, remarkable cell morphologic al-
terations were observed in SW620 cells with SOX2 knock-
down compared with the parental SW620 cells, with the cells
displaying a compact shape and lacked ruffles, protrusions on
their surfaces (Fig. 3D).
Identification of SOX2 regulated genes by microarrays
We used Affymetrix array U133 plus 2 to identify genes
regulated by SOX2 by comparing expression profiles of pa-
rental SW620 cells and SOX2-knockdown SW620 cells. Data
were submitted to GEO with the accession number GSE20689.
We found that the expression of 1,715 probes (corresponding
to 1,205 genes and 124 unannotated probes) was decreased by
twofold or more in the SOX2 knockdown SW620 cells com-
paring with the mock control cells (Supplementary Table 3). In
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addition, 2,109 probes (corresponding to 1,381 annotated
genes, and 182 unannotated probes) were upregulated in
SOX2-knockdown cells compared with the mock control cells.
To further validate the SOX2-responsive gene expression
detected by microarrays, we selected six genes (ST14, MTSS1,
NGFRAP1, FGFR2, Jun, and CDKN2C) and determined their
expression by real-time-PCR. We confirmed the expression
of ST14, MTSS1, NGFRAP1, Jun, FGFR2, and CDKN2C in
SW620 cells of SOX2 knockdown comparing to that in the
controls (Fig. 4A).
Gene Ontology (GO) analysis of downregulated genes by
SOX2 knockdown revealed that the GO terms cell surface
receptor linked signal transduction (GO: 0007166), BMP sig-
naling pathway (GO:0030509), response to retinoic acid
(GOL0032526), response to vitamin A (GO: 0033189), and
steroid metabolic process (GO:0008202) were enriched at FDR
<0.05 (Table 1). However, there were no significantly (FDR
<0.05) enriched GO terms for the genes that were upregulated
by SOX2 known down.
We also analyzed the differentially expressed genes
using GSEA with the C2:CP gene sets, which is the collec-
tion of the pathways from various data bases, http://www
.broadinstitute.org/gsea/msigdb/collection_details.jsp). We
found the SOX2 upregulated genes (i.e., those under ex-
FIG. 1. Upregulation of SOX2 in human colorectal carcinomas. (A) A bar chart showing real-time PCR of SOX2 in colon
adenocarcinomas tissue (T, tumor tissue) and normal tissue mucosa (N, normal tissue). Y-axis, normalized relative expression
levels. (B) Immunostaining for SOX2 protein in tissue of carcinomas and adjacent normal tissue mucosa. Top: representative
pictures of carcinomas (left) and normal tissue (right). Bottom: a summary of the IHC findings. (C) Western blot detection of
SOX2 protein (38 kDa) in different colon cancer cell lines.
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pressed in SOX2 knockdown cells compared to MOCK knock
down cells) were enriched for many pathways including
HSA04514 cell adhesion molecules, HSA04670 leukocyte
transendothelial migration, HSA01430 cell communication,
HSA04530 tight junction, etc. ( p< 0.05) (Supplementary Table 4).
Key genes regulated by SOX2 and their functions are listed in
Table 2.
ChIP-seq analysis of SOX2 binding sites
in colorectal cancer cells
In order to understand the genome-wide binding patterns
of SOX2, we applied ChIP-seq technology, which is a novel
approach for identifying transcription factor binding sites
genome-wide (Barski et al., 2007; Jothi et al., 2008). We per-
formed replicate SOX2 ChIP and IgG ChIP. After sequencing
analysis. We obtained 13,437,404 and 16,165,014 raw reads,
respectively, for SOX2_ChIP and IgG_ChIP, and 7,241,344
and 8,291,710 passed the default quality filter of the GA
pipeline of Illumina Inc., respectively. We then applied MACS
to identify SOX2 enriched binding regions (Zhang et al., 2008).
We identified 1,086 enriched SOX2 binding region in the
human genome with mfold¼ 32 and p-value cutoff<1.00E-05
(Supplementary Table 5). We randomly picked 10 genes for
which the promoter regions are enriched for the SOX2 IP, and
we were able to confirm all 10 genes to be enriched in the
SOX2 IP DNAs compared to the IGG-IP DNAs using real-time
quantitative PCR (Fig. 4B), suggesting that the false positive
rate is negligible in our dataset.
We mapped the SOX2 binding regions to genes using
the UCSC human genome annotations (hg19) using a distance
of 50 kb as the cutoff value (Supplementary Table 5). We
FIG. 2. Knockdown of Sox2 inhibits cell growth in colorectal cells. (A) Analysis of SOX2 RNA levels by RT-PCR in SOX2
knockdown SW620 cells and SW620 MOCK knockdown cells. (B) Western blot analysis of SOX2 protein expression in SOX2
knockdown SW620 cells and SW620 MOCK knockdown cells. (C) Effect of SOX2 knockdown on cell proliferation by MTT
assay. The asterisks indicate statistical significance at p< 0.01. (D) Cell cycle analysis SOX2 knockdown SW620 cells and
SW620 MOCK knockdown cells by FACS. A summary table is provided for cells in different stages of cell cycles. (E)
Evaluation of apoptosis in SOX2 knockdown SW620 cells and SW620 MOCK knockdown cells. The percentage of cells
entering apoptosis was determined by FACS analysis using FITC-labeled annexin V kit and shown at the bottom panel.
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found that 676 (62.3%) SOX2 binding regions could be
mapped to within 50 kb of TSS or TES of genes. Among them,
only 136 (20%) mapped to within 10 kb of TSSs and 56 map-
ped to within 2 kb of TSSs, suggesting that the majority of
the SOX2 binding sites are far away from proximal promoter
regions.
Using the homologene table for human and mouse from
NCBI (http://www.ncbi.nlm.nih.gov/homologene), we com-
pared the SOX2 targets that we identified in CRC cells with the
sox2 targets that were identified in mouse ES cells (Chen et al.,
2008a). We identified 122 common targets (Table 3). Many
interesting genes were among the common targets including
two other SOX family members (SOX5 and SOX6), tumor
suppressor or oncogene such as WT1 (Wilms tumor 1) and
PIM1 (Pim-1 oncogene), two catennins {CTNNA3 [Catenin
(cadherin-associated protein), alpha 3] and CTNNBL1 (Cate-
nin, beta like 1)}, several solute carrier proteins including
SLC23A2 [Solute carrier family 23 (nucleobase transporters),
member 2], SLC24A3 (Solute carrier family 24, sodium/
potassium/calcium exchanger, member 3), SLC35F1 (Solute
FIG. 3. SOX2 knockdown decreases cell colony formation on soft agar, in vivo tumorigenesis potential and migratory
property of SW620 cells. (A) Sox2 knockdown SW620 cells and SW620 MOCK knockdown cells were analyzed for their
ability to form colonies. Data are representatives of three independent experiments. The asterisk indicates statistical signif-
icance at p< 0.01. (B) Growth rates of SOX2 knockdown SW620 cells and SW620 MOCK knockdown cells in in vivo mouse
model. Volumes of tumors were monitored every week. Y-axis, tumor volumes; X-axis, weeks after inoculation of cells. The
asterisk indicates statistical significance at p< 0.01. Bottom: representative pictures of tumor samples. (C) A wound-healing
assay of SOX2 knockdown SW620 cells and SW620 MOCK knockdown cells. Photographs were taken at the time of 0 h and
72 h time points. Representative photos from one of three replicate experiments are shown (100original magnification). (D)
Morphological alterations of SW620 cells with SOX2 knockdown. The Sox2 knockdown cells show a compact shape
and lacked ruffles, protrusions on their surfaces compared with MOCK knockdown cells. Photos shown at 200 and 400
original magnification.
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carrier family 35, member F1), SLC35F3 (Solute carrier family
35, member F3), and HDAC9 (Histone deacetylase 9). These
data demonstrated versatile functions of SOX2.
An integrative analysis of SOX2 ChIP-seq data and ex-
pression profiling data revealed that only 94 of the 676 SOX2
binding regions (that could be mapped to within 50 kb of a
gene) (about 14%) changed in gene expression (Supplemen-
tary Table 5). Among them, 53 SOX2 binding regions showed
positive correlation (i.e., SOX2 binding would result in over-
expression) and 41 SOX2 binding region showed negative
FIG. 4. Validation of differentially expressed genes and ChIP-seq targets by RT-PCR and the consensus sequence of SOX2
binding. (A) Expression of ST14, MTSS1, FGFR2, CDKN2C, NGFRAP1, and Jun was analyzed with real-time PCR in SOX2
knockdown and MOCK knockdown SW620 cells. (B) Quantitative real-time PCR for the confirmation of ChIP-seq peaks.
Relative amount of PCR products from SOX2–ChIP and IgG–ChIP are shown as bar graphs. Standard deviations are also
shown. (C) The DNA binding consensus sequence of SOX2 in SW620 cells identified by the MotifSampler program. (D) The
DNA binding consensus sequence of the mouse ES cells from Chen et al. (2008a) and reanalyzed by the motifSampler
program. (E) Cytoscape network view of SOX2 and its key interacting proteins. Direction lines showed direct SOX2-DNA
binding interaction from our data and the lines ending with cycles indicate negative regulation information derived from
literatures. The network was drawn with the Cytoscape program.
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correlation (SOX2 binding would result in under expression)
(Supplementary Table 5).
Identification of DNA binding consensus and SOX2
collaborating TFs in the SOX2 binding regions
To see whether the human SOX2 binding regions in CRC
cells have their own unique and enriched binding motif, we
used the MotifSampler program (http://homes.esat.kuleuven
.be/*thijs/Work/MotifSampler.html) (Thijs et al., 2002a,
2002b) to identify binding consensus sequences enriched in
the SOX2 binding regions that we identified. We found a
consensus sequence wwTGywTT (Fig. 4C) with a very high
log-likelihood score of 1,535.58. The output matrix for this
consensus sequence is shown in Supplementary Document 6,
and there are 628 instances of this motif in 1086 SOX2 binding
regions (Supplementary Table 5). The consensus logo is
shown in Figure 4C. We were curious whether the sequence
motif shows any similarities to known binding motifs. Using
JASPAR: an open-access database for eukaryotic transcription
factor binding profiles (http://jaspar.genereg.net/) (Sandelin
et al., 2004), we found that the highest ranked match is to
FOX11 (matrix MA0042.1) with a score of 7.6 and a percent
score of 95.39. FOX11 belongs to the forkead family tran-
scription factor, winged helix-turn-helix class. SOX2 belongs
to the High Mobility Group (HMG) transcription factor, other
alpha-helix class (http://jaspar.genereg.net/).
We then wondered whether known TFs could bind to the
SOX2 binding regions that we identified and act as SOX2
cooperators for the regulation of gene expression. In order to
systematically search for potential bindings of other tran-
scription factors, we used the MotifScanner program (http://
homes.esat.kuleuven.be/*thijs/download.html) and scan-
ned all TF motif matrices (PWM databases) using the human
transcription factor subset of the Transfac professional 7.0.
Matched matrices with likelihood (LR) ratios of 500 or higher
were tabulated and frequencies calculated (Supplementary
Table 7). We found that three transcription factor OCT1,
SOX1, and CEBP seem to colocalize at>50% of the times with
SOX2 (Supplementary Table 7).
Discussion
In the present study, we have demonstrated that expression
levels of SOX2 mRNA and SOX2 protein were frequently
overexpressed in primary colorectal cancer tissues (Fig. 1A
and B) ( p< 0.01). We knocked down the expression of SOX2
SW620 colorectal cancer cell lines, and found that reduced
expression of SOX2 correlates with decreased growth rates,
colony formation, and migration abilities of SW620 cells
(Figs. 2C and 3A–C). In addition, knocking down of SOX2
resulted in an accumulation of cells in the G0/G1 phases and a
decrease of cells in S and G2/M phases (Fig. 2D). However,
the knockdown of SOX2 expression had no measurable effect
on the apoptosis of SW620 cells (Fig. 2E). Using in vivo mouse
models, we showed that SOX2 knockdown cells had reduced
tumor sizes compared with the MOCK known down cells
(Fig. 3B). Taken together, these data suggested functional
important roles of SOX2 in colorectal carcinogenesis. Ex-
pression changes revealed by DNA microarray analysis
showed that many pathways involved in cell adhesion, cell
communication, cell migration, tight junction, fatty acid me-
tabolism, mitochondria pathway, TGF-beta signaling are en-
riched in the MOCK transfected cells (Supplementary Table
4). These expression changes may explain the underlying
mechanism of different growth and migration properties of
SOX2 knock down and MOCK knock down cells.
An examination of the cell morphological changes revealed
that the SOX2 knockdown SW620 cells had a compact shape
and lacked ruffles, protrusions on their surfaces compared
with control cells (Fig. 3D). Furthermore, by IHC staining, we
detected dramatic increase of nuclear localization of SOX2
proteins in colorectal cancer cells compared with cells from
normal adjacent tissues (Fig. 1B), suggesting a process of
nuclear translocation and accumulation of SOX2 during co-
lorectal cancer carcinogenesis. These data suggested that
SOX2 have dramatic effects on cell morphology and cellular
biology. It would be of great interest to study the mechanism
and the role in cell growth control of SOX2 nuclear translo-
cation as well as the underlying mechanisms for its role in
induction of morphological changes.
Table 1. Enriched GO Terms for SOX2-Regulated Genes in CRC
GO category Changed genes Enrichment Log10(p)
Downregulated genes by SOX2 knockdown
GO:0007165_signal_transduction 1,064 169 1.34
GO:0007154_cell_communication 1,175 182 1.31
GO:0007166_cell_surface_receptor_linked_signal_transduction 384 71 1.56
GO:0008544_epidermis_development 54 17 2.66
GO:0032501_multicellular_organismal_process 989 152 1.30
GO:0030509_BMP_signaling_pathway 19 9 4.00
GO:0021700_developmental_maturation 12 7 4.92
GO:0007398_ectoderm_development 61 18 2.49
GO:0042060_wound_healing 53 16 2.55
GO:0007167_enzyme_linked_receptor_protein_signaling_pathway 147 32 1.84
GO:0007275_multicellular_organismal_development 706 111 1.33
GO:0001501_skeletal_system_development 73 19 2.20
GO:0009611_response_to_wounding 126 28 1.88
GO:0008202_steroid_metabolic_process 52 15 2.44
GO:0032526_response_to_retinoic_acid 11 6 4.60
GO:0033189_response_to_vitamin_A 11 6 4.60
GO:0051240_positive_regulation_of_multicellular_organismal_process 47 14 2.51
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Table 2. Key Genes Regulated by SOX2 and Their Functions
ACVR1 Activin A receptor, type I BMP signaling pathway
BMP2 Bone morphogenetic protein 2 BMP signaling pathway
BMP4 Bone morphogenetic protein 4 BMP signaling pathway
BMPR2 Bone morphogenetic protein receptor,
type II (serine/threonine kinase)
BMP signaling pathway
PCSK6 Proprotein convertase subtilisin/
kexin type 6
BMP signaling pathway
SMAD5 SMAD family member 5 BMP signaling pathway
SMAD6 SMAD family member 6 BMP signaling pathway
SMAD7 SMAD family member 7 BMP signaling pathway
SMURF1 SMAD specific E3 ubiquitin
protein ligase 1
BMP signaling pathway
PCSK6 Proprotein convertase subtilisin/
kexin type 6
cell surface receptor linked signal transduction
IGF1R Insulin-like growth factor 1 receptor cell surface receptor linked signal transduction
GNA15 Guanine nucleotide binding protein
(G protein), alpha 15 (Gq class)
cell surface receptor linked signal transduction
TGFB2 Transforming growth factor, beta 2 cell surface receptor linked signal transduction
RGS3 Regulator of G-protein signaling 3 cell surface receptor linked signal transduction
FGFR3 Fibroblast growth factor receptor 3
(achondroplasia, thanatophoric dwarfism)
cell surface receptor linked signal transduction
IL6ST Interleukin 6 signal transducer
(gp130, oncostatin M receptor)
cell surface receptor linked signal transduction
EREG Epiregulin cell surface receptor linked signal transduction
SOCS5 Suppressor of cytokine signaling 5 cell surface receptor linked signal transduction
IRAK1 Interleukin-1 receptor-associated
kinase 1
cell surface receptor linked signal transduction
PIK3R1 Phosphoinositide-3-kinase, regulatory
subunit 1 (p85 alpha)
cell surface receptor linked signal transduction
EDN1 Endothelin 1 cell surface receptor linked signal transduction
OPN3 Opsin 3 (encephalopsin, panopsin) cell surface receptor linked signal transduction
PYCARD PYD and CARD domain containing cell surface receptor linked signal transduction
SMURF1 SMAD specific E3 ubiquitin protein ligase 1 cell surface receptor linked signal transduction
SIGIRR Single immunoglobulin and
toll-interleukin 1 receptor (TIR) domain
cell surface receptor linked signal transduction
CD24 CD24 molecule cell surface receptor linked signal transduction
SMAD7 SMAD family member 7 cell surface receptor linked signal transduction
AGRN Agrin cell surface receptor linked signal transduction
RHOQ Ras homolog gene family, member Q cell surface receptor linked signal transduction
IRS1 Insulin receptor substrate 1 cell surface receptor linked signal transduction
MAML3 Mastermind-like 3 (Drosophila) cell surface receptor linked signal transduction
GNB2 Guanine nucleotide binding protein
(G protein), beta polypeptide 2
cell surface receptor linked signal transduction
COL16A1 Collagen, type XVI, alpha 1 cell surface receptor linked signal transduction
MTSS1 Metastasis suppressor 1 cell surface receptor linked signal transduction
TRIB1 Tribbles homolog 1 (Drosophila) cell surface receptor linked signal transduction
PTK2 PTK2 protein tyrosine kinase 2 cell surface receptor linked signal transduction
BMPR2 Bone morphogenetic protein receptor,
type II (serine/threonine kinase)
cell surface receptor linked signal transduction
IFITM1 interferon induced transmembrane
protein 1
cell surface receptor linked signal transduction
ACVR1 Activin A receptor, type I cell surface receptor linked signal transduction
CCRL2 Chemokine (C-C motif) receptor-like 2 cell surface receptor linked signal transduction
TACSTD2 Tumor-associated calcium signal
transducer 2
cell surface receptor linked signal transduction
PTPRF Protein tyrosine phosphatase,
receptor type, F
cell surface receptor linked signal transduction
SMAD3 SMAD family member 3 cell surface receptor linked signal transduction
DGKQ Diacylglycerol kinase, theta 110 kDa cell surface receptor linked signal transduction
SRC V-src sarcoma (Schmidt-Ruppin A-2)
viral oncogene homolog (avian)
cell surface receptor linked signal transduction
BMP4 Bone morphogenetic protein 4 cell surface receptor linked signal transduction
EGFR Epidermal growth factor receptor
(erythroblastic leukemia viral (v-erb-b)
oncogene homolog, avian)
cell surface receptor linked signal transduction
SMAD5 SMAD family member 5 cell surface receptor linked signal transduction
(continued)
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Table 2. (Continued)
DGKH Diacylglycerol kinase, eta cell surface receptor linked signal transduction
KLK6 Kallikrein-related peptidase 6 cell surface receptor linked signal transduction
GAB1 GRB2-associated binding protein 1 cell surface receptor linked signal transduction
VIPR1 Vasoactive intestinal peptide receptor 1 cell surface receptor linked signal transduction
BMP2 Bone morphogenetic protein 2 cell surface receptor linked signal transduction
PARD3 Par-3 partitioning defective 3 homolog
(C. elegans)
cell surface receptor linked signal transduction
CD14 CD14 molecule cell surface receptor linked signal transduction
ROR1 Receptor tyrosine kinase-like
orphan receptor 1
cell surface receptor linked signal transduction
ADAM17 ADAM metallopeptidase domain 17
(tumor necrosis factor, alpha,
converting enzyme)
cell surface receptor linked signal transduction
ADAM10 ADAM metallopeptidase domain 10 cell surface receptor linked signal transduction
NUP62 Nucleoporin 62 kDa cell surface receptor linked signal transduction
LEPR Leptin receptor cell surface receptor linked signal transduction
P2RY2 Purinergic receptor P2Y, G-protein
coupled, 2
cell surface receptor linked signal transduction
AFAP1L2 actin filament associated protein
1-like 2
cell surface receptor linked signal transduction
AREG Amphiregulin (schwannoma-derived
growth factor)
cell surface receptor linked signal transduction
HPGD Hydroxyprostaglandin dehydrogenase
15-(NAD)
cell surface receptor linked signal transduction
STAT3 Signal transducer and activator of
transcription 3 (acute-phase response factor)
cell surface receptor linked signal transduction
CXCL1 Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
cell surface receptor linked signal transduction
GPR37 G protein-coupled receptor 37 (endothelin
receptor type B-like)
cell surface receptor linked signal transduction
CD59 CD59 molecule, complement regulatory
protein
cell surface receptor linked signal transduction
LY6E Lymphocyte antigen 6 complex, locus E cell surface receptor linked signal transduction
CBLC Cas-Br-M (murine) ecotropic retroviral
transforming sequence c
cell surface receptor linked signal transduction
PPAP2A Phosphatidic acid phosphatase type 2A cell surface receptor linked signal transduction
PSENEN Presenilin enhancer 2 homolog (C. elegans) cell surface receptor linked signal transduction
THBS1 Thrombospondin 1 cell surface receptor linked signal transduction
DEFB1 Defensin, beta 1 cell surface receptor linked signal transduction
SMAD6 SMAD family member 6 cell surface receptor linked signal transduction
NMUR2 Neuromedin U receptor 2 cell surface receptor linked signal transduction
ADRA2A Adrenergic, alpha-2A-, receptor cell surface receptor linked signal transduction
CENTA1 Centaurin, alpha 1 cell surface receptor linked signal transduction
RGS2 Regulator of G-protein signaling 2, 24kDa cell surface receptor linked signal transduction
ITPR3 Inositol 1,4,5-triphosphate receptor, type 3 cell surface receptor linked signal transduction
RBP4 Retinol binding protein 4, plasma response to retinoic acid
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 response to retinoic acid
RXRA Retinoid X receptor, alpha response to retinoic acid
AQP3 Aquaporin 3 (Gill blood group) response to retinoic acid
RARA Retinoic acid receptor, alpha response to retinoic acid
TRIM16 Tripartite motif-containing 16 response to retinoic acid
RBP4 Retinol binding protein 4, plasma response to vitamin A
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 response to vitamin A
RXRA Retinoid X receptor, alpha response to vitamin A
AQP3 Aquaporin 3 (Gill blood group) response to vitamin A
RARA Retinoic acid receptor, alpha response to vitamin A
TRIM16 Tripartite motif-containing 16 response to vitamin A
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As a vital step toward comprehensive understanding the
molecular mechanism of SOX2 function, we set to identify
SOX2 regulated genes (all potential genes) by comparing
SOX2 knockdown colorectal cancer cells with MOCK knock-
down cancer cells. We identified 1,205 genes and 124 unan-
notated genes that are potentially regulated by SOX2
(Supplementary Table 3). GO analysis revealed that SOX2 is
involved the many important biological processes (GO terms)
including cell surface receptor-linked signal transduction
(GO: 0007166), BMP signaling pathway (GO:0030509), re-
sponse to retinoic acid (GO:0032526), response to vitamin A
(GO: 0033189), and steroid metabolic process (GO:0008202)
(Table 1). Looking further into the detailed gene lists identi-
fied to be regulated by SOX2 in these GO terms, we found that
SOX2 regulated 9 out of 19 genes in the BMP signaling
pathway (GO: 0030509) including SMAD5, SMAD6, SMAD7,
BMP2, and BMP7, ACVR1 (activin Receptor 1), PCSK6,
SMURF1, and BMPR2 (Table 2). SMAD proteins were found
to be involved in colorectal cancers. For example, SAMD7 was
found to induce hepatic metastasis in colorectal cancer
(Halder et al., 2008). SOX2 also regulated many genes that cell
surface receptor that are signaling molecules including
TGFB2, IGF1R, FGFR3, and EGFR (Table 2), suggesting that
SOX2 is probably a master gene that control all these receptor
mediated signaling pathways. Many of these pathways have
been implicated in colorectal cancers. For example, IGF1R
(insulin-like growth factor 1 receptor) enhances invasion and
induces resistance to apoptosis of colon cancer cells (Sekhar-
am et al., 2003). The EGFR expression was shown to correlate
with more aggressive disease and a poorer prognosis of co-
lorectal cancers, and EGFR is considered a critical target for
the treatment of colorectal cancers (O’Dwyer and Benson,
2002). Hu et al. (2010) showed that EGFR–SOX2–EGFR forms
a feedback loop that positively regulates the self-renewal of
neural precursor cells. Our data showed that SOX2 regulated
EGFR. However, whether such an EGFR–SOX2–EGFR feed-
back loop exists in colorectal cancer cells or their stem cells
remain to be investigated.
In order to differentiate SOX2 directly regulated genes from
SOX2 indirect regulated genes, we applied ChIP-seq, a novel
global technology in identifying transcriptional factor binding
sites (Barski et al., 2007; Johnson et al., 2007), to the identifi-
cation of global SOX2 binding sites in colorectal cancer cells.
We identified 1,086 significantly enriched SOX2 binding re-
gion in the human genome (Supplementary Table 5). Among
them, only 136 (20%) mapped to within 10 kb of transcription
start sites (TSSs) of genes, and majority mapped to >10 kb
from TSSs, suggesting that SOX2 is probably an enhancer
binding transcription factors (i.e., activator) rather than a
promoter binding transcription factor. Indeed, only 46 (6.8%)
SOX2 binding regions could be mapped to within 1 kb of
TSSs. An interesting observation is that SOX2 binds to two
enhancer regions in SOX5 and to one enhancer region in SOX6
(Supplementary Table 5), suggesting a regulatory mechanism
within the SOX family proteins. However, the resulting
binding did not change the expression of SOX5 and SOX6,
judged by two fold changes from the comparison of SOX2
knockdown to MOCK cells.
Analysis of the consensus sequences bound to SOX2 re-
vealed a consensus sequence of wwTGywTT (W¼A, T;
Y¼C, T), a GC rich dinucleotide sequence core surrounded
by three AT-rich sequences on each site. Our consensus motif
is similar to the last eight nucleotides (the reverse and com-
plement stand sequence TTWGCATA,) of the 15-nucleotide
consensus sequence identified in embryonic stem cells (Chen
et al., 2008a). As there are many programs for identifying
DNA binding motifs from DNA binding sequence data in-
cluding AlignACE (Roth et al., 1998), MEME (Bailey et al.,
2006), MotifSampler (Thijs et al., 2002a, 2002b), and PoS-
SuMsearch (Beckstette et al., 2006), and Chen et al. used their
custom written program for analyzing their mouse ES SOX2
ChIP-seq data, it would be best to compare the motif identi-
fied using the sample motif finding program. We therefore
analyzed the mouse SOX2 ChIP-seq data from Chen’s article
(Chen et al., 2008a) using the MotifSampler program and the
same parameters that we used to colorectal cancer SOX2
ChIP-seq data analysis, and we found that the eight nucleo-
tide motif is wwTkmwTw (K¼G, T; M¼A, C) (Fig. 4C),
which is similar to wwTGywTT (Fig. 4D) that we found for
the SOX2 in colorectal cancer cells.
We found that 53 and 41 SOX2 binding regions showed
positive and negative correlation with expression changes of
genes respectively (Supplementary Table 5). These suggest that
other transcription factor or coactivators also play a role in the
final outcome of the SOX2 binding. Interesting positive corre-
lated genes include WT1 (Wilms tumor 1), ITPR2 (Inositol
1,4,5-triphosphate receptor, type 2), HDAC4 (Histone deace-
tylase 4), and HDAC9 (Histone deacetylase 9). WT1 gene is
overexpressed in colorectal cancers (Oji et al., 2003). ITPR2
plays an important role in intracellular Ca2þ signaling and
phosphatidylinositol signaling (KEGG pathway HSA04020
and HSA04070). Histone modification has been shown to be an
important process for carcinogenesis (Esteller, 2007). HDAC1
are overexpressed in colorectal cancers (Ishihama et al., 2007)
and HDAC inhibitors sensitize colorectal cancer cells to
chemotherapy and radiotherapy (Chen et al., 2009; Flis et al.,
2009). We showed that two histone modification enzymes
HDAC4 and HDAC9 are regulated by SOX2. This finding is
novel and may provide a link between histone modification
and stem cell gene SOX2. However, additional experiments
need to be carried out for confirm this observation.
The negative correlated genes include RUNX2 (Runt-
related transcription factor 2) and IGF1R (Insulin-like growth
factor 1 receptor). Wai et al. (2006) showed that murine
RUNX2 regulated transcription of a metastatic gene, osteo-
pontin, in murine colorectal cancer cells. The insulin-like
growth factor I receptor (IGF-I-R) plays a critical role in cell
growth, transformation, and apoptosis. In many cancers in-
cluding colorectal cancers, it is overexpressed and functions
as an antiapoptotic agent by enhancing cell survival (Baserga
et al., 1997; Donovan and Kummar, 2008; Hakam et al., 1999).
The mechanism controlling IGF1R is complex. Multiple pro-
teins including P53, WT1, P63, and P73 were shown to inhibit
IGF1R expression (Nahor et al., 2005; Werner et al., 1996). Our
data added SOX2 as a negative regulator of IGF1R in colo-
rectal cancer cells. A network view of the above relationships
is shown in Figure 4E.
Conclusion
We showed for the first time that SOX2 is overexpressed in
CRC tissues compared with normal adjacent tissues, and that
knockdown of SOX2 in colorectal cancer cells decreased their
growth rates using both in vitro cell line and in vivo xenograft
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Table 3. Common SOX2 Targets in CRC Cells and Mouse ES Cells Identified through
the NCBI’s Homologene Table
Homo sapiens GeneID Mus musculus GeneID Description
ABCA4 24 Abca4 11304 ATP-binding cassette, subfamily A (ABC1),
member 4
ACTR2 10097 Actr2 66713 ARP2 actin-related protein 2 homolog (yeast)
ADCY5 111 Adcy5 224129 Adenylate cyclase 5
ADK 132 Adk 11534 Adenosine kinase
AFF3 3899 Aff3 16764 AF4/FMR2 family, member 3
AKAP7 9465 Akap7 432442 A kinase (PRKA) anchor protein 7
ALDH1L2 160428 Aldh1l2 216188 Aldehyde dehydrogenase 1 family,
member L2
ALK 238 Alk 11682 Anaplastic lymphoma kinase (Ki-1)
ANGPT1 284 Angpt1 11600 Angiopoietin 1
ANKRD55 79722 Ankrd55 77318 Ankyrin repeat domain 55
ARHGAP10 79658 Arhgap10 78514 Rho GTPase activating protein 10
ARID2 196528 Arid2 77044 AT rich interactive domain 2 (ARID, RFX-like)
ASCC1 51008 Ascc1 69090 Activating signal cointegrator 1 complex
subunit 1
BCMO1 53630 Bcmo1 63857 Beta-carotene 15,150-monooxygenase 1
BTBD9 114781 Btbd9 224671 BTB (POZ) domain containing 9
C11orf61 79684 BC024479 235184 Chromosome 11 open reading frame 61
CBFA2T2 9139 Cbfa2t2 12396 Core-binding factor, runt domain, alpha
subunit 2; translocated to, 2
CDH12 1010 Cdh12 215654 Cadherin 12, type 2 (N-cadherin 2)
CDH4 1002 Cdh4 12561 Cadherin 4, type 1, R-cadherin (retinal)
CDKAL1 54901 Cdkal1 68916 CDK5 regulatory subunit associated
protein 1-like 1
CDS1 1040 Cds1 74596 CDP-diacylglycerol synthase
(phosphatidate cytidylyltransferase) 1
CHD1L 9557 Chd1l 68058 Chromodomain helicase DNA binding
protein 1-like
CHI3L1 1116 Chi3l1 12654 Chitinase 3-like 1 (cartilage glycoprotein-39)
CLYBL 171425 Clybl 69634 Citrate lyase beta like
CNTNAP2 26047 Cntnap2 66797 Contactin associated protein-like 2
CNTNAP4 85445 Cntnap4 170571 Contactin associated protein-like 4
COL18A1 80781 Col18a1 12822 Collagen, type XVIII, alpha 1
COL4A1 1282 Col4a1 12826 Collagen, type IV, alpha 1
CTNNA3 29119 Ctnna3 216033 Catenin (cadherin-associated protein), alpha 3
CTNNBL1 56259 Ctnnbl1 66642 Catenin, beta like 1
DENND1A 57706 Dennd1a 227801 DENN/MADD domain containing 1A
DEPDC6 64798 Depdc6 97998 DEP domain containing 6
DIAPH3 81624 Diap3 56419 Diaphanous homolog 3 (Drosophila)
DLGAP1 9229 Dlgap1 224997 Discs, large (Drosophila) homolog-associated
protein 1
DNAJC15 29103 Dnajc15 66148 DnaJ (Hsp40) homolog, subfamily C,
member 15
DOCK4 9732 Dock4 238130 Dedicator of cytokinesis 4
DOK5 55816 Dok5 76829 Docking protein 5
DTNA 1837 Dtna 13527 Dystrobrevin, alpha
DTNB 1838 Dtnb 13528 Dystrobrevin, beta
DTX4 23220 Dtx4 207521 Deltex 4 homolog (Drosophila)
ETV1 2115 Etv1 14009 Ets variant gene 1
EXT1 2131 Ext1 14042 Exostoses (multiple) 1
EYA4 2070 Eya4 14051 Eyes absent homolog 4 (Drosophila)
FBXL18 80028 Fbxl18 231863 F-box and leucine-rich repeat protein 18
FER 2241 Fert2 14158 Fer (fps/fes related) tyrosine kinase
(phosphoprotein NCP94)
FRMD4A 55691 Frmd4a 209630 FERM domain containing 4A
GRHL2 79977 Grhl2 252973 Grainyhead-like 2 (Drosophila)
GRPEL2 134266 Grpel2 17714 GrpE-like 2, mitochondrial (E. coli)
HDAC9 9734 Hdac9 79221 Histone deacetylase 9
HNF4G 3174 Hnf4g 30942 Hepatocyte nuclear factor 4, gamma
HS2ST1 9653 Hs2st1 23908 Heparan sulfate 2-O-sulfotransferase 1
IGF1R 3480 Igf1r 16001 Insulin-like growth factor 1 receptor
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Table 3. (Continued)
Homo sapiens GeneID Mus musculus GeneID Description
IMMP2L 83943 Immp2l 93757 IMP2 inner mitochondrial membrane
peptidase-like (S. cerevisiae)
ITGA1 3672 Itga1 109700
JRK 8629 Jrk 16469 Jerky homolog (mouse)
KIAA0182 23199 Gse1 382034 KIAA0182
KIAA1383 54627 4933403G14Rik 74393 KIAA1383
KLF12 11278 Klf12 16597 Kruppel-like factor 12
KRAS 3845 Kras 16653 V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog
LAMA1 284217 Lama1 16772 Laminin, alpha 1
LAMA4 3910 Lama4 16775 Laminin, alpha 4
LOC647309 647309 Gm606 239789 Hypothetical LOC647309
LRP1B 53353 Lrp1b 94217 Low density lipoprotein-related protein 1B
(deleted in tumors)
LSAMP 4045 Lsamp 268890 Limbic system-associated membrane protein
LYST 1130 Lyst 17101 Lysosomal trafficking regulator
MPP6 51678 Mpp6 56524 Membrane protein, palmitoylated 6 (MAGUK
p55 subfamily member 6)
MSI2 124540 Msi2 76626 Musashi homolog 2 (Drosophila)
MT4 84560 Mt4 17752 Metallothionein 4
MTHFD1L 25902 Mthfd1l 270685 Methylenetetrahydrofolate dehydrogenase
(NADPþdependent) 1-like
MYB 4602 Myb 17863 V-myb myeloblastosis viral oncogene
homolog (avian)
MYO1E 4643 Myo1e 71602 Myosin IE
NRARP 441478 Nrarp 67122 Notch-regulated ankyrin repeat protein
NRP1 8829 Nrp1 18186 Neuropilin 1
PANX1 24145 Panx1 55991 Pannexin 1
PDE4D 5144 Pde4d 238871 Phosphodiesterase 4D, cAMP-specific
(phosphodiesterase E3 dunce homolog,
Drosophila)
PDIA4 9601 Pdia4 12304 Protein disulfide isomerase family A, member 4
PIK3R3 8503 Pik3r3 18710 Phosphoinositide-3-kinase, regulatory subunit 3
(p55, gamma)
PIM1 5292 Pim1 18712 Pim-1 oncogene
PLCH1 23007 Plch1 269437 Phospholipase C, eta 1
PLEKHA5 54477 Plekha5 109135 Pleckstrin homology domain containing, family
A member 5
PRKRIR 5612 Prkrir 72981 Protein-kinase, interferon-inducible double
stranded RNA dependent inhibitor,
repressor of (P58 repressor)
PTPRK 5796 Ptprk 19272 Protein tyrosine phosphatase,
receptor type, K
PTPRT 11122 Ptprt 19281 Protein tyrosine phosphatase,
receptor type, T
RAD51L1 5890 Rad51l1 19363 RAD51-like 1 (S. cerevisiae)
RBMS1 5937 Rbms1 56878 RNA binding motif, single stranded
interacting protein 1
REPS1 85021 Reps1 19707 RALBP1 associated Eps domain containing 1
RPS6KA2 6196 Rps6ka2 20112 Ribosomal protein S6 kinase, 90kDa, polypeptide 2
RTEL1 51750 Rtel1 269400
RTTN 25914 Rttn 246102 Rotatin
RUNX1T1 862 Runx1t1 12395 Runt-related transcription factor 1;
translocated to, 1 (cyclin D-related)
SCHIP1 29970 Schip1 30953 Schwannomin interacting protein 1
SERINC5 256987 Serinc5 218442 Serine incorporator 5
SETX 23064 Setx 269254 Senataxin
SHC4 399694 Shc4 271849 SHC (Src homology 2 domain containing)
family, member 4
SLC23A2 9962 Slc23a2 54338 Solute carrier family 23 (nucleobase
transporters), member 2
SLC24A3 57419 Slc24a3 94249 Solute carrier family 24 (sodium/potassium/
calcium exchanger), member 3
SLC35F1 222553 Slc35f1 215085 Solute carrier family 35, member F1
(continued)
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models, suggesting its essential roles in the tumorigenesis
of colorectal cancers. Applying next-generation sequencing
coupled with Chromatin IP, we identified a consensus se-
quence wwTGywTT for SOX2 binding to promoter/enhancer
regions of its regulated genes in colorectal cancers. An inte-
grated expression profiling and ChIP-seq analysis show that
SOX2 is involved in the BMP signaling pathway, steroid
metabolic process, histone modifications, and many receptor-
mediated signaling pathways such as IGF1R and ITPR2 (In-
ositol 1,4,5-triphosphate receptor, type 2).
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